F Khosrow-Khavar1, K B Filion1, S Al-Qurashi2, N Torabi3, N Bouganim4, S Suissa1, L Azoulay1. 1. Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada. 2. Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada 3. McGill Library, McGill University, Montreal, Quebec, Canada. 4. Department of Oncology, Cedar Cancer Center, McGill University Health Center, Montreal, Canada.
Abstract
Background: Aromatase inhibitors (AIs) have been associated with cardiovascular disease in adjuvant randomized controlled trials (RCTs) comparing these drugs to tamoxifen. However, it is unclear whether this risk is real or due to cardioprotective effects of tamoxifen. To address this question, we conducted a systematic review and meta-analysis of all RCTs of AIs and tamoxifen in adjuvant and extended adjuvant setting. Patients and methods: We searched PubMed, Embase (OVID), Cochrane CENTRAL, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov from inception to June 2016 for all RCTs comparing cardiovascular and cerebrovascular safety of AIs to tamoxifen, AIs to placebo or no-treatment, or tamoxifen to placebo or no-treatment in the adjuvant or extended adjuvant setting. Relative risks (RRs) were pooled using DerSimonian and Laird random-effects models with analyses stratified by RCT design. Results: A total of 19 RCTs were included in the meta-analysis (n = 62 345). In the adjuvant setting, AIs were associated with a 19% (RR: 1.19, 95% confidence interval [CI]: 1.07-1.34) increased risk of cardiovascular events compared with tamoxifen. AIs were not associated with an increased risk compared with placebo in the extended-adjuvant setting (RR: 1.01, 95% CI: 0.85-1.20). In the adjuvant setting, tamoxifen was associated with a 33% (RR: 0.67, 95% CI: 0.45-0.98) decreased risk compared with placebo or no-treatment. The results from extended adjuvant RCTs comparing tamoxifen to placebo were inconclusive but suggestive of a small protective effect (RR: 0.91, 95% CI: 0.77-1.07). Conclusions: The increased risk of cardiovascular events with AIs relative to tamoxifen is likely the result of cardioprotective effects of the latter. This new evidence should be considered when assessing the benefits and risks of AIs in the treatment of breast cancer.
Background: Aromatase inhibitors (AIs) have been associated with cardiovascular disease in adjuvant randomized controlled trials (RCTs) comparing these drugs to tamoxifen. However, it is unclear whether this risk is real or due to cardioprotective effects of tamoxifen. To address this question, we conducted a systematic review and meta-analysis of all RCTs of AIs and tamoxifen in adjuvant and extended adjuvant setting. Patients and methods: We searched PubMed, Embase (OVID), Cochrane CENTRAL, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov from inception to June 2016 for all RCTs comparing cardiovascular and cerebrovascular safety of AIs to tamoxifen, AIs to placebo or no-treatment, or tamoxifen to placebo or no-treatment in the adjuvant or extended adjuvant setting. Relative risks (RRs) were pooled using DerSimonian and Laird random-effects models with analyses stratified by RCT design. Results: A total of 19 RCTs were included in the meta-analysis (n = 62 345). In the adjuvant setting, AIs were associated with a 19% (RR: 1.19, 95% confidence interval [CI]: 1.07-1.34) increased risk of cardiovascular events compared with tamoxifen. AIs were not associated with an increased risk compared with placebo in the extended-adjuvant setting (RR: 1.01, 95% CI: 0.85-1.20). In the adjuvant setting, tamoxifen was associated with a 33% (RR: 0.67, 95% CI: 0.45-0.98) decreased risk compared with placebo or no-treatment. The results from extended adjuvant RCTs comparing tamoxifen to placebo were inconclusive but suggestive of a small protective effect (RR: 0.91, 95% CI: 0.77-1.07). Conclusions: The increased risk of cardiovascular events with AIs relative to tamoxifen is likely the result of cardioprotective effects of the latter. This new evidence should be considered when assessing the benefits and risks of AIs in the treatment of breast cancer.
Authors: Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson Journal: N Engl J Med Date: 2011-06-04 Impact factor: 91.245
Authors: C Markopoulos; M Chrissochou; A Michailidou; E Tzoracoleftherakis; G Xepapadakis; J Papadiamantis; J Misitzis; V Zobolas; D Bafaloukos; H Gogas Journal: Anticancer Drugs Date: 2005-09 Impact factor: 2.248
Authors: A Buzdar; A Howell; J Cuzick; C Wale; W Distler; G Hoctin-Boes; J Houghton; G Y Locker; J M Nabholtz Journal: Lancet Oncol Date: 2006-08 Impact factor: 41.316
Authors: F J Cummings; R Gray; D C Tormey; T E Davis; H Volk; J Harris; G Falkson; J M Bennett Journal: J Clin Oncol Date: 1993-01 Impact factor: 44.544
Authors: J Cuzick; D Allen; M Baum; J Barrett; G Clark; V Kakkar; E Melissari; C Moniz; J Moore; V Parsons Journal: Eur J Cancer Date: 1992 Impact factor: 9.162
Authors: Saamir A Hassan; Nicolas Palaskas; Peter Kim; Cezar Iliescu; Juan Lopez-Mattei; Elie Mouhayar; Rohit Mougdil; Kara Thompson; Jose Banchs; Syed Wamique Yusuf Journal: Curr Atheroscler Rep Date: 2018-02-08 Impact factor: 5.113
Authors: Kelly C Gast; Paul V Viscuse; Somaira Nowsheen; Tufia C Haddad; Robert W Mutter; Andrea E Wahner Hendrickson; Fergus J Couch; Kathryn J Ruddy Journal: Curr Treat Options Cardiovasc Med Date: 2018-03-01
Authors: Vanessa B Sheppard; Chiranjeev Dash; Sarah Nomura; Arnethea L Sutton; Robert Lee Franco; Alexander Lucas; Masey Ross; Lucile Adams-Campbell Journal: Cancer Date: 2020-07-02 Impact factor: 6.860
Authors: Judy N Jacobse; Lars C Steggink; Michael Schaapveld; Gabe S Sonke; Annemiek van Ommen-Nijhof; Joop D Lefrandt; Jourik A Gietema; Flora E van Leeuwen Journal: Breast Cancer Res Treat Date: 2022-10-01 Impact factor: 4.624
Authors: Jennifer L Lund; Krishnan Bhaskaran; Anthony A Matthews; Sharon Peacock Hinton; Susannah Stanway; Alexander Richard Lyon; Liam Smeeth Journal: Heart Date: 2020-11-11 Impact factor: 5.994